Key Highlights

  • Third quarter net loss was USD 81.7 million, or USD 0.37 per share, versus USD 74.1 million, or USD 0.43 per share, a year earlier.
  • Cash, cash equivalents and investments totaled USD 848.6 million at September 30, 2026, which the company expects to fund operations into 2029.
  • Research and development expense rose to USD 77.1 million from USD 68.3 million, while general and administrative expense was USD 13.1 million versus USD 12.1 million.
  • Nine-month financing included USD 296.8 million from a May follow-on offering and USD 159.2 million from at-the-market sales, both net.

Loss Widens as Phase 3 Spending Builds

Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company, filed its Quarterly Report on November 4, 2026 for the period ended September 30, 2026. It reported no Revenue in the quarter, and a net loss of USD 81.7 million. Research and Development was USD 77.1 million versus USD 68.3 million, and general and administrative expense was USD 13.1 million versus USD 12.1 million, so operating expenses were USD 90.2 million versus USD 80.4 million. Nine-month research and development was USD 224.2 million. Interest income rose to USD 8.5 million from USD 6.4 million. The nine-month net loss was USD 238.7 million, or USD 1.19 per share, and nine-month revenue was USD 3.4 million versus USD 8.4 million. The weighted share count rose to 219.2 million from 172.4 million, which is why the per-share loss fell. Unrealized losses on investments of USD 3.8 million took the comprehensive loss to USD 85.6 million.

How the Cash Pile Was Built

Cash rose through Equity raising rather than operations. In May 2026, the company completed a follow-on offering of 26,354,167 shares for net proceeds of USD 296.8 million, and it raised another USD 159.2 million net through at-the-market sales in the nine months. Net cash from financing was USD 466.9 million for the period. Management says the USD 848.6 million of cash, equivalents and investments will fund operating and Capital Expenditure requirements into 2029, on assumptions that may prove wrong. It will need to raise more capital to continue developing its pipeline and to commercialize any approved drug. Each raise dilutes existing holders.

Zovegalisib Phase 3 Is the Value Driver

Relay Therapeutics (NASDAQ:RLAY) is advancing zovegalisib, which it describes as the first known allosteric, pan-mutant and isoform-selective PI3Kα inhibitor in clinical development. The global Phase 3 ReDiscover-2 trial started in the second quarter of 2025 and compares zovegalisib plus fulvestrant against capivasertib plus fulvestrant in previously treated HR+/HER2- breast cancer. The FDA granted Breakthrough Therapy Designation in February 2026. In April 2026, the company selected atirmociclib, an investigational drug from Pfizer, as its triplet combination partner. Its Dynamo platform combines computational and experimental approaches to drug protein targets that were previously hard to address. Other programs include RLY-8161, an NRAS-selective inhibitor in a clinical trial for NRAS-mutant melanoma and other solid tumors, a Fabry disease chaperone and a TIE2 inhibitor for vascular anomalies.

Where Things Stand

On management's own estimate, the cash covers operating expenses into 2029. Relay Therapeutics (NASDAQ:RLAY) loses about USD 80 million a quarter, so the runway depends on spending staying near current levels and on trial progress. The estimate may be wrong, the company says it will need more capital, and approval is not assured. The Phase 3 ReDiscover-2 trial is the main event to follow.